AI is becoming more essential as scientific data is becoming more abundant and more accessible. In order to offer high-quality evidence-based solutions our AI models are trained across massive federated datasets that contain millions of data points. AI-based solutions can then be employed to augment the cognitive abilities of individual scientists and teams to enable them to make more informed decisions in drug design.
Generative AI provides a way to rapidly generate novel molecules. There has been an explosion in generative models using neural networks. Massive virtual libraries of compounds can be rapidly generated to explore new and exciting areas of chemical space.
Structure based drug design is heavily reliant upon high quality protein structures. Rapidly docking virtual molecules to proteins of interest is a computationally demanding problem.
Pending AI Inc.
1 Broadway, Cambridge,,
Massachusetts,
United States, 02142
Pending AI Pty Ltd.
The National Innovation Centre,
Suite 112, 4 Cornwallis St.,
Eveleigh,
NSW 2015, Australia
contact@pending.ai